Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Abstract Background The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) a...

Descrizione completa

Dettagli Bibliografici

Autori principali:	P. Neven, P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G. V. Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, J. P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. J. Slamon
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-08-01
Serie:	Breast Cancer Research
Soggetti:	Ribociclib CDK4/6 inhibitor Advanced breast cancer Overall survival First line
Accesso online:	https://doi.org/10.1186/s13058-023-01701-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!